Stock Track | Anavex Life Sciences Soars 5.61% on Analyst Upgrade and Higher Price Target on Approval Prospects

Stock Track

Dec 26, 2024

Anavex Life Sciences Corp. (AVXL) shares surged 5.61% in pre-market trading on Thursday, after H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on the stock and raised the price target from $40 to $42, citing the company's strong financial position and prospects for European approval of its lead drug candidate.

According to Selvaraju, Anavex's robust cash position and potential European approval for its Alzheimer's drug candidate, blarcamesine, drove the positive outlook and higher price target. The analyst expects the company's cash runway to extend well into 2025, supporting its development efforts.

Selvaraju highlighted blarcamesine's promising clinical data and regulatory pathway, anticipating potential approval in Europe next year. The drug candidate is currently under review by the European Medicines Agency (EMA) for the treatment of Alzheimer's disease.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1156115353"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1156115353\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1156115353?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-12-26 22:42","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1156115353","market":"hk","top_or_hot":-1,"title":"Stock Track | Anavex Life Sciences Soars 5.61% on Analyst Upgrade and Higher Price Target on Approval Prospects","media":"Stock Track","content":"<p>Anavex Life Sciences Corp. (AVXL) shares surged 5.61% in pre-market trading on Thursday, after H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on the stock and raised the price target from $40 to $42, citing the company's strong financial position and prospects for European approval of its lead drug candidate.</p>\n\n<p>According to Selvaraju, Anavex's robust cash position and potential European approval for its Alzheimer's drug candidate, blarcamesine, drove the positive outlook and higher price target. The analyst expects the company's cash runway to extend well into 2025, supporting its development efforts.</p>\n\n<p>Selvaraju highlighted blarcamesine's promising clinical data and regulatory pathway, anticipating potential approval in Europe next year. The drug candidate is currently under review by the European Medicines Agency (EMA) for the treatment of Alzheimer's disease.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Anavex Life Sciences Soars 5.61% on Analyst Upgrade and Higher Price Target on Approval Prospects</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Anavex Life Sciences Soars 5.61% on Analyst Upgrade and Higher Price Target on Approval Prospects\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2024-12-26 22:42</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Anavex Life Sciences Corp. (AVXL) shares surged 5.61% in pre-market trading on Thursday, after H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on the stock and raised the price target from $40 to $42, citing the company's strong financial position and prospects for European approval of its lead drug candidate.</p>\n\n<p>According to Selvaraju, Anavex's robust cash position and potential European approval for its Alzheimer's drug candidate, blarcamesine, drove the positive outlook and higher price target. The analyst expects the company's cash runway to extend well into 2025, supporting its development efforts.</p>\n\n<p>Selvaraju highlighted blarcamesine's promising clinical data and regulatory pathway, anticipating potential approval in Europe next year. The drug candidate is currently under review by the European Medicines Agency (EMA) for the treatment of Alzheimer's disease.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"AVXL","symbol_name":"Anavex Life Sciences Corp.","start_time":0,"source_url":"","article_id":"1156115353","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1156115353","pubTimestamp":1735224164,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Anavex Life Sciences Corp.  shares surged 5.61% in pre-market trading on Thursday, after H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on the stock and raised the price target from $40 to $42, citing the company's strong financial position and prospects for European approval of its lead drug candidate.According to Selvaraju, Anavex's robust cash position and potential European approval for its Alzheimer's drug candidate, blarcamesine, drove the positive outlook and higher price t","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"AVXL":"Anavex Life Sciences Corp."},"translate_title":"Anavex Life Sciences股票因分析师升级和批准前景上调目标价而飙升5.61%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AVXL":1},"content_text":"Anavex Life Sciences Corp. (AVXL) shares surged 5.61% in pre-market trading on Thursday, after H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on the stock and raised the price target from $40 to $42, citing the company's strong financial position and prospects for European approval of its lead drug candidate.\nAccording to Selvaraju, Anavex's robust cash position and potential European approval for its Alzheimer's drug candidate, blarcamesine, drove the positive outlook and higher price target. The analyst expects the company's cash runway to extend well into 2025, supporting its development efforts.\nSelvaraju highlighted blarcamesine's promising clinical data and regulatory pathway, anticipating potential approval in Europe next year. The drug candidate is currently under review by the European Medicines Agency (EMA) for the treatment of Alzheimer's disease.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}